{"id":1161118,"date":"2026-11-02T21:07:18","date_gmt":"2026-11-02T21:07:18","guid":{"rendered":"https:\/\/www.europesays.com\/us\/1161118\/"},"modified":"2026-11-02T21:07:18","modified_gmt":"2026-11-02T21:07:18","slug":"ipo-news-renaissance-capitals-october-ipo-market-update","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/1161118\/","title":{"rendered":"IPO News &#8211; Renaissance Capital\u2019s October IPO Market Update"},"content":{"rendered":"<p>&#13;<br \/>\n                        Eight IPOs raised a combined $1.2 billion in October, joined by one direct listing. Activity was well below the month\u2019s 10-year historical average (22 IPOs, $5.1B). Six IPOs raised $100 million or more. With AI stocks under pressure in recent weeks, biotechs dominated the docket, accounting for seven of the month\u2019s nine listings. Protein degrader biotech <strong>Lycia Therapeutics<\/strong> (<a class=\"profilelink\" href=\"https:\/\/www.renaissancecapital.com\/Profile\/LYCA\" rel=\"nofollow noopener\" target=\"_blank\">LYCA<\/a>) completed the largest offering, upsizing and pricing at the top of the range to raise $318 million before soaring 67% in its debut. Despite issuing a pricing announcement, SoftBank-backed Nigerian fintech <strong>OPay<\/strong> (<a class=\"profilelink\" href=\"https:\/\/www.renaissancecapital.com\/Profile\/OPAY\" rel=\"nofollow noopener\" target=\"_blank\">OPAY<\/a>) did not complete its $304 million US IPO and never commenced trading. The month\u2019s traditional IPOs averaged an 8% return from offer, though nearly two-thirds finished below issue, as solid gains from a few offset mostly small losses. The Renaissance IPO Index sank 10% in October, compared to the S&amp;P 500\u2019s 1% loss. New filing activity slowed, with 19 companies submitting initial filings, though the pipeline got a major boost from AI giant <strong>Anthropic<\/strong> (<a class=\"profilelink\" href=\"https:\/\/www.renaissancecapital.com\/Profile\/ANT\" rel=\"nofollow noopener\" target=\"_blank\">ANT<\/a>), which filed for an IPO we estimate could raise $75 billion and vie with SpaceX for the largest listing ever. Despite the recent pressure on AI stocks, Anthropic\u2019s expected mid-November listing should be the main event of the 4Q. A strong debut could encourage the other large AI names on file to list before year end and set the stage for a robust start to 2027.<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2026\/11\/Screenshot 2026-11-02 151209.png\" alt=\"ENTER ALT TAG HERE\" style=\"display:block;margin-left:auto;margin-right:auto;\"\/><br \/><strong>To read the rest of the article, sign up for a free trial of <a href=\"https:\/\/ipopro.renaissancecapital.com\/Pricing?utm_source=October2026Update&amp;utm_medium=blog&amp;utm_campaign=October2026Update\" target=\"_blank\" rel=\"nofollow noopener\">IPO Pro<\/a>, the platform that gives you all of the IPO information you need, all in one place.<\/strong><\/p>\n<p><a href=\"https:\/\/ipopro.renaissancecapital.com\/Pricing?utm_source=October2026Update&amp;utm_medium=blog&amp;utm_campaign=October2026Update\" target=\"_blank\" class=\"button\" rel=\"nofollow noopener\">Start a Free Trial of <strong>IPO Pro<\/strong><\/a><br \/><a href=\"https:\/\/ipopro.renaissancecapital.com\/Pricing?utm_source=October2026Update&amp;utm_medium=blog&amp;utm_campaign=October2026Update\" target=\"_blank\" rel=\"nofollow noopener\"><img decoding=\"async\" src=\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2026\/11\/Feb2026Update_public.png\" alt=\"Sign up for a free trial of IPO Pro\" width=\"100%\" style=\"display:block;margin-left:auto;margin-right:auto;\"\/><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"&#13; Eight IPOs raised a combined $1.2 billion in October, joined by one direct listing. Activity was well&hellip;\n","protected":false},"author":3,"featured_media":1161119,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[13],"tags":[462343,462341,64,462340,462342,57409,18316,462339,462345,135,462344,67,132,68],"class_list":["post-1161118","post","type-post","status-publish","format-standard","has-post-thumbnail","category-markets","tag-aspe","tag-bbtx","tag-business","tag-cty","tag-iam","tag-initial-public-offerings","tag-ipos","tag-lyca","tag-lycia-therapeutics","tag-markets","tag-opay","tag-united-states","tag-unitedstates","tag-us"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/117548891823546594","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/1161118","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=1161118"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/1161118\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/1161119"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=1161118"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=1161118"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=1161118"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}